⚠ Evidence warning: Clinical trials or other evidence do not support the claim that ringworm bush leaf treats ringworm, tinea imbricata and pityriasis versicolor. This page keeps it as a report of what people, websites or other media say.
Ringworm Bush — Benefits Deep Dive
The most surprising fact this set turned up is not about the antifungal claim ringworm bush is named for. It is that the plant's single best piece of clinical evidence — an actual three-arm randomised controlled trial with a real placebo group — is for the laxative effect its own main page cautions against. (The only other placebo-controlled human trials found are two small Philippine trials of a ringworm bush lotion for scabies, which a 2025 review rated very low certainty; see the ledger.) That single fact reorganises everything else here. Four pages follow the evidence rather than the plant's marketing, folk name or the brief that first proposed them: they broaden "wound healing" into the much larger antibacterial literature it actually has; they name a specific, checkable reason the antioxidant and anti-inflammatory claims are the weakest tier despite generating the largest raw search count; and they trace one compound family, the anthraquinones, through a benefit (plausible topical antimicrobial action), a proven effect (the laxative randomized controlled trial, RCT), and a hazard (potassium loss and dependence on chronic internal use) that are all, mechanistically, the same story.
Deep-Dive Articles
Antifungal Activity and Ringworm Treatment
The plant's namesake claim, taken further than the main page can go: the real mechanism (including a 2024 computational docking result against the same enzyme azole drugs hit), the strong in-vitro record with real minimum inhibitory concentration (MIC) arithmetic against pharmaceutical standards, and three separate pieces of human evidence — a prospective Philippine tinea imbricata study, a Nigerian schoolchildren susceptibility survey, and an old, unverifiable 1994 report — each with a distinct and different limitation, none of them a controlled trial.
Read the deep dive →Laxative Effect and Anthraquinone Chemistry
The plant's best-evidenced claim by far — a real 1990 Thai randomized controlled trial against placebo and an active comparator — and the potassium-loss and dependence hazards that anthraquinone laxatives carry with chronic use. The mechanism, the quantified anthraquinone chemistry, a direct real-world parallel (rhein's career as the drug diacerein), a checked-and-rejected coumarin caution, and a genotoxicity signal reported at exactly the size it was found.
Read the deep dive →Antibacterial Activity and Skin Infections
Why "wound healing" undersold this plant's second-largest evidence base. A cellulitis-specific Staphylococcus aureus study with real MIC numbers, a methicillin-resistant S. aureus finding traced to a specific compound and structural requirement, modern anti-biofilm and anti-quorum-sensing mechanisms, and the closest thing to actual wound-healing evidence this plant has — human keratinocyte migration data, reported with exactly the caveat that distinguishes it from a clinical trial.
Read the deep dive →Antioxidant, Anti-Inflammatory and Other Preclinical Claims
The largest raw literature and the weakest evidence tier, explained rather than asserted. Includes the doctrine's tyrosinase trap caught in the wild — two real studies that support cosmetic skin-lightening, not the repigmentation a reader recovering from tinea versicolor might hope for — plus a part-substitution flag on the antidiabetic claim (flower, not leaf) and the acarbose ceiling that bounds what its mechanism could plausibly achieve.
Read the deep dive →Table of Contents
- Deep-Dive Articles
- Evidence Ledger
- One Mechanism, Three Faces
- A Note on How This Set Diverged From Its Brief
- Key Research: Antifungal Activity
- Key Research: Laxative Effect and Chemistry
- Key Research: Antibacterial Activity
- Key Research: Antioxidant, Anti-Inflammatory and Other Claims
- External Resources
- Connections
- Featured Videos
Evidence Ledger
Claims ranked by the strength of what actually supports them, not by how famous they are or how many search results they generate.
Best supported — randomised controlled trials
- Ringworm bush leaves work as a stimulant laxative. Evidence: an 80-patient, three-arm randomized controlled trial against placebo and an active comparator (mist. alba), statistically significant, from 1990. Within 24 hours, 18 per cent of the placebo group passed stools, against 86 per cent with mist. alba and 83 per cent with the ringworm bush infusion (P < 0.001); nausea, dyspepsia, abdominal pain and diarrhoea were noted in 16–25 per cent of patients (Thamlikitkul 1990, listed under Key Research below). Verdict: the strongest single human trial for any claim on this plant; the only other placebo-controlled trials are the two small scabies trials below. Anthraquinone laxatives as a class cause potassium loss and dependence with chronic use, as set out on the laxative page.
- A ringworm bush (akapulko) lotion clears scabies lesions. Evidence: a 2025 systematic review of randomised trials in Filipino patients found two trials (157 participants) comparing Senna alata lotion with placebo. Complete clearance of lesions was more frequent with the lotion (RR 4.94, 95% CI 1.67 to 14.62), but the reviewers rated this very low certainty evidence and stated they were uncertain about the difference; no serious adverse events were reported across the included studies — PubMed PMID: 41502969. Verdict: placebo-controlled, but small and of very low certainty.
Real human evidence, three different kinds of incomplete
- Topical leaf decoction improves symptoms of tinea imbricata. Evidence: a prospective, objectively measured, uncontrolled 2020 study, N=20. Verdict: real improvement in validated symptom and severity scores — after 4 weeks, 95 per cent had lower itch (pruritus) scores on a visual analogue scale, with a mean decrease of 4.05; mycological clearance on the potassium hydroxide (KOH) skin-scraping test only 40 per cent; no placebo arm — PubMed PMID: 32779266.
- Dermatophytes respond to this plant in the lab. Evidence: a 2009 Nigerian study testing organisms freshly isolated from infected schoolchildren. Verdict: real and clinically relevant susceptibility data; not a treatment trial — no child was treated with the plant.
- The plant treats Pityriasis versicolor. Evidence: a 1994 report in the Journal of Ethnopharmacology describing "a 10-year human study" — PubMed PMID: 8046939. Verdict: old and positive; the abstract gives no patient numbers, and the methodology is not verifiable from the available record.
Laboratory only, real and repeated
- Antifungal and antibacterial activity in vitro. Evidence: a large, decades-deep, multi-continent literature, with real comparative MIC data against pharmaceutical standards — in a 1992 study the water extract’s MIC was 1.6 mg/ml against E. coli (chloramphenicol 2 ug/ml) and 0.39 mg/ml against Candida albicans (amphotericin B 0.58 ug/ml) (Crockett 1992, listed below). Verdict: consistent screening-level activity, roughly 700–800× weaker by weight than the drugs it was measured against.
- Activity against methicillin-resistant Staphylococcus aureus, traced to two specific compounds with a defined structural requirement. Evidence: one well-designed fractionation study, in which kaempferol and aloe-emodin showed MIC50 values of 13.0 ± 1.5 and 12.0 ± 1.5 microg/mL, and “a free hydroxyl group at C-3 of the flavonol structure” was the structural requirement — PubMed PMID: 18991205. Verdict: specific and mechanistically coherent; untested against an actual methicillin-resistant Staphylococcus aureus (MRSA) infection.
- Anti-biofilm and anti-quorum-sensing activity. Evidence: two independent studies using modern mechanistic assays. Verdict: real, in-vitro, untested in any infection model.
Single-study or preliminary
- Human keratinocyte migration ("wound healing") data. Evidence: one 2025 cell-culture study, non-toxic concentrations (no significant reduction in cell viability up to 200 µg/mL), measurable migration-rate improvement (best at 50 µg/mL, 5.89 ± 0.80 µm/h over 96 hours), and S. aureus MIC 0.625 mg/mL (Lee 2025, listed below). Verdict: the closest thing to wound-healing evidence this plant has; a dish, not a wound.
- A novel analgesic/anti-inflammatory alkaloid (cassiaindoline) and a second analgesic flavonoid glycoside. Evidence: two specific, structurally characterised rodent studies, injected route. Verdict: real pharmacology; never followed up; not tested by any route a person would actually use.
- Anti-inflammatory activity in a chronic, immune-mediated rat arthritis model. Evidence: one 2011 study, oral route, 28-day observation. Verdict: the most disease-relevant animal model in this set; single and unreplicated.
- An antidiabetic compound (emodin) isolated and characterised. Evidence: one rigorous 2020 rat study. Verdict: real, but from the flower, not the leaf that carries the rest of this plant's evidence, and in a beta-cell-ablation model that represents insulin deficiency more than the insulin resistance of type 2 diabetes.
Checked and qualified or refused
- "Improves skin tone after tinea versicolor." Verdict: refused. The tyrosinase-inhibition data behind any such claim supports cosmetic skin-lightening, the opposite mechanism from repigmentation. Full explanation on the antioxidant page.
- "Contains coumarins, therefore thins the blood." Verdict: does not apply. This plant's documented chemistry is anthraquinones and flavonoids, not coumarins; the real bleeding-risk pathway runs through diarrhoea-driven vitamin K disruption instead.
- A weak genotoxicity (Ames) signal and in-vitro DNA binding by a purified flavonoid glycoside. Verdict: reported at its actual size — one positive tester strain, one purified fraction — neither dismissed nor inflated into a cancer warning.
Mechanistically necessary harms, from the same chemistry that produces the benefits above
- Potassium loss, dependence and dose unpredictability on chronic internal use. Evidence: well established for anthraquinone laxatives as a class. Verdict: the direct cost of the same compound family responsible for the randomized controlled trial-proven laxative effect and the plausible topical antimicrobial action.
One Mechanism, Three Faces
Read top to bottom, the ledger above traces a single chemical thread. The anthraquinones — chiefly aloe-emodin, rhein, emodin and chrysophanol — are lipophilic, membrane-active compounds. Applied to skin, that property plausibly disrupts a fungal or bacterial cell membrane (the antifungal and antibacterial pages). Swallowed, the same compounds — travelling as sugar-bound glycosides until gut bacteria free them in the colon — produce a genuine, randomized controlled trial-proven laxative effect, and with chronic use, the electrolyte and dependence risks that are this plant's most serious documented hazard (the laxative page). One compound family; a benefit and a hazard that are, mechanistically, the same fact stated in two different tissues. Rhein's own separate career as the active metabolite of the osteoarthritis drug diacerein — whose most common side effect is diarrhoea — is a real-world demonstration of exactly this duality, entirely independent of this plant.
A Note on How This Set Diverged From Its Brief
The brief that proposed this set suggested "wound-healing and skin-infection use" as a third topic alongside antifungal activity, laxative chemistry and antioxidant/anti-inflammatory claims. A species-locked search for wound-healing evidence specifically returned a small handful of records — far too thin to support a dedicated page at the depth the rest of this set was written to. A search for antibacterial activity broadly, which subsumes the traditional wound and insect-bite use without being limited to it, returned nearly ten times as many records, including the plant's most clinically pointed finding (activity against methicillin-resistant Staphylococcus aureus, traced to a specific compound and a defined structural requirement) and its closest approach to real wound-healing evidence (human keratinocyte migration data). The third page was built around that broader, better-evidenced topic instead, and is titled accordingly. The brief was treated as a starting hypothesis and checked against the literature before the pages were written.
Key Research: Antifungal Activity
- Eusebio-Alpapara KMV, Dofitas BL, Balita-Crisostomo CLA, et al. Senna (Cassia) alata (Linn.) Roxb. leaf decoction as a treatment for tinea imbricata in an indigenous tribe in Southern Philippines. Mycoses, 2020;63(11):1226-1234 — the best human study. PubMed PMID: 32779266
- Eja ME, Arikpo GE, Enyi-Idoh KH, Etim SE, Etta HE. Efficacy of local herbal therapy in the management of dermatophytosis among primary school children in Cross River State, South-south Nigeria. African Journal of Medicine and Medical Sciences, 2009;38(2):135-41 — the Nigerian schoolchildren dermatophytosis survey. PubMed PMID: 20175416
- Saptarini NM, Mustarichie R, Hasanuddin S, Corpuz MJT. Cassia alata L.: A Study of Antifungal Activity against Malassezia furfur, Identification of Major Compounds, and Molecular Docking to Lanosterol 14-Alpha Demethylase. Pharmaceuticals (Basel), 2024;17(3) — lanosterol demethylase docking. PubMed PMID: 38543166
- Crockett CO, Guede-Guina F, Pugh D, et al. Cassia alata and the preclinical search for therapeutic agents for the treatment of opportunistic infections in AIDS patients. Cell and Molecular Biology, 1992;38(5):505-11 — comparative MIC data against chloramphenicol and amphotericin B. PubMed PMID: 1468110
- Damodaran S, Venkataraman S. A study on the therapeutic efficacy of Cassia alata, Linn. leaf extract against Pityriasis versicolor. Journal of Ethnopharmacology, 1994;42(1):19-23 — the 1994 pityriasis versicolor report. PubMed PMID: 8046939
- Comparative trial literature for topical terbinafine and clotrimazole — the pharmaceutical benchmark. — Search PubMed
Key Research: Laxative Effect and Chemistry
- Thamlikitkul V, Bunyapraphatsara N, Dechatiwongse T, et al. Randomized controlled trial of Cassia alata Linn. for constipation. Journal of the Medical Association of Thailand, 1990;73(4):217-22 — the flagship trial of this entire set. PubMed PMID: 2203870
- Panichayupakaranant P, Sakunpak A, Sakunphueak A. Quantitative HPLC determination and extraction of anthraquinones in Senna alata leaves. Journal of Chromatographic Science, 2009;47(3):197-200 — validated high-performance liquid chromatography (HPLC) anthraquinone quantification. PubMed PMID: 19298705
- Hennebelle T, Weniger B, Joseph H, Sahpaz S, Bailleul F. Senna alata. Fitoterapia, 2009;80(7):385-93 — comprehensive chemistry and pharmacology review. PubMed PMID: 19446609
- Anthraquinone laxatives and hypokalaemia.
- Melanosis coli and chronic anthraquinone use.
Key Research: Antibacterial Activity
- Hazni H, Ahmad N, Hitotsuyanagi Y, Takeya K, Choo CY. Phytochemical constituents from Cassia alata with inhibition against methicillin-resistant Staphylococcus aureus (MRSA). Planta Medica, 2008;74(15):1802-5 — MRSA-active compounds and structural requirement. PubMed PMID: 18991205
- Toh SC, Lihan S, Bunya SR, Leong SS. In vitro antimicrobial efficacy of Cassia alata (Linn.) leaves, stem, and root extracts against cellulitis causative agent Staphylococcus aureus. BMC Complementary Medicine and Therapies, 2023;23(1):85 — cellulitis-associated S. aureus. PubMed PMID: 36934252
- Rekha PD, Vasavi HS, Vipin C, Saptami K, Arun AB. A medicinal herb Cassia alata attenuates quorum sensing in Chromobacterium violaceum and Pseudomonas aeruginosa. Letters in Applied Microbiology, 2017;64(3):231-238 — quorum-sensing inhibition. PubMed PMID: 28035685
- Lee SK, Keng JW, Yon JA, et al. Phytochemical Analysis and Biological Activities of Flavonoids and Anthraquinones from Cassia alata (Linnaeus) Roxburgh and Their Implications for Atopic Dermatitis Management. Plants (Basel), 2025;14(3):362 — human keratinocyte migration data. PubMed PMID: 39942922
- Saito ST, Trentin Dda S, Macedo AJ, et al. Bioguided Fractionation Shows Cassia alata Extract to Inhibit Staphylococcus epidermidis and Pseudomonas aeruginosa Growth and Biofilm Formation. Evidence-Based Complementary and Alternative Medicine, 2012;2012:867103 — anti-biofilm activity and compound identification. PubMed PMID: 22548121
Key Research: Antioxidant, Anti-Inflammatory and Other Claims
- Chatatikun M, Chiabchalard A. Thai plants with high antioxidant levels, free radical scavenging activity, anti-tyrosinase and anti-collagenase activity. BMC Complementary and Alternative Medicine, 2017;17(1):487 — tyrosinase and collagenase inhibition, cosmetic framing. PubMed PMID: 29121910
- Uwazie JN, Yakubu MT, Ashafa AOT, Ajiboye TO. Identification and characterization of anti-diabetic principle in Senna alata (Linn.) flower using alloxan-induced diabetic male Wistar rats. Journal of Ethnopharmacology, 2020;261:112997 — flower-derived antidiabetic compound. PubMed PMID: 32534114
- Lewis A, Levy A. Anti-inflammatory activities of Cassia alata leaf extract in complete Freund’s adjuvant arthritis in rats. West Indian Medical Journal, 2011;60(6):615-21 — complete Freund’s adjuvant (CFA)-induced arthritis model. PubMed PMID: 22512217
- Villaseñor IM, Sanchez AC. Cassiaindoline, a new analgesic and anti-inflammatory alkaloid from Cassia alata. Zeitschrift für Naturforschung C, 2009;64(5-6):335-8 — cassiaindoline, novel alkaloid. PubMed PMID: 19678534
- Pasion GCS, Montilla LP, Genuino RF. Efficacy and Safety of Gliricidia sepium, Senna alata, and Tinospora rumphii in the Treatment of Filipino Patients with Scabies: A Systematic Review and Meta-analysis. Acta Medica Philippina, 2025;59(18):16-37 — the two placebo-controlled scabies lotion trials. PubMed PMID: 41502969
- PubMed: Acarbose and HbA1c, the drug-class ceiling for the antidiabetic mechanism.
External Resources
- PubMed — the index behind every search link on these five pages; the composition of a search return, not just its size, is information.
- National Center for Complementary and Integrative Health (U.S. National Institutes of Health) — plain-language summaries of herb and supplement evidence generally.
- U.S. Food and Drug Administration Drug Safety and Availability — for anyone considering a concentrated internal preparation of any anthraquinone-bearing plant.
- Plants of the World Online (Kew) — the botanical authority for Senna alata, its accepted name, synonyms and distribution.
- Cochrane Library — systematic reviews of topical antifungal treatment, for comparison with the evidence on these pages.
Connections
- All Herbs
- Ringworm Bush (Senna alata) — the main article, with names, identification, the Philippine Department of Health endorsement, and full dosage and caution detail.
- Antifungal Activity and Ringworm Treatment — the flagship claim.
- Laxative Effect and Anthraquinone Chemistry — the best-evidenced claim, and the hazards of chronic internal use.
- Antibacterial Activity and Skin Infections — the plant's largest evidence base beyond the fungus it is named for.
- Antioxidant, Anti-Inflammatory and Other Preclinical Claims — the weakest tier, and why.
- Senna (Senna alexandrina) — the standardised pharmaceutical laxative this plant is constantly confused with.
- Neem — the other major topical antimicrobial plant of the region.
- Tea Tree — the topical antifungal with the deepest human-trial base, for comparison.
- Aloe Vera — another anthraquinone-bearing plant with the same soothing-versus-laxative split.
- Ringworm — the clinical condition.
- Tinea Versicolor — the Malassezia condition, and where the tyrosinase caution matters most.
- Staphylococcus Aureus — the organism behind the methicillin-resistant Staphylococcus aureus and cellulitis findings.
- Dermatology — the full skin-disease library.